# US 5,348,740 A · Antigenic polypeptides of Taenia ovis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,348,740 A
- Document ID: US5348740A
- Status: Granted
- Kind: A
- Application number: 07/851,112
- Filed: 1992-03-16
- Granted: 1994-09-20
- Earliest claimed: 1988-05-12
- Assignees: Coopers Animal Health NZ Limited; The University of Melbourne; Ministry of Agriculture & Fisheries
- Inventors: Gavin B. L. Harrison; Robert P. Dempster; Michael D. Rickard; Marshall W. Lightowlers; Kim L. O'Hoy; Kevin S. Johnson; David D. Heath; Stephen B. Lawrence; Jennifer G. Vinton
- Web page: https://patentgrep.com/patent/US5348740A

## CPC

- C07K 14/43554: {from Taenia}
- C07K 16/18: against material from animals or humans
- C12N 9/1088: {Glutathione transferase (2.5.1.18)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/23: containing a GST-tag
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to polypeptide antigens of T.ovis suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by expression of DNA coding therefor in a recombinant host cell. Aspects of the invention include DNA encoding the antigens, vectors containing the DNA and hosts which express the antigens. The invention also provides antibody and DNA probes for use in identifying protective antigens of cestode parasites other than T.ovis.

## Claims

### Claim 1

An antigenic T. ovis polypeptide essentially free from T. ovis components occurring in nature and running as a 47-52 kDa doublet on SDS-PAGE, which reduces the severity of T. ovis infection in a ruminant.

### Claim 2 (depends on 1)

A composition suitable for reducing the severity of T. ovis infection in a ruminant, said composition comprising an effective amount of an antigenic polypeptide as claimed in claim 1 in association with a pharmaceutically acceptable carrier or adjuvant.

### Claim 3

An antigenic T. ovis polypeptide, 45W, essentially free from T. ovis components occurring in nature and running as a 47-52 kD doublet on SDS-PAGE, which reduces the severity of T.ovis infection in a ruminant, said antigenic polypeptide consisting essentially of the amino acid sequence: ##STR1##

### Claim 4 (depends on 3)

An antigenic polypeptide as claimed in claim 3, consisting of the amino acid sequence: ##STR2##

### Claim 5 (depends on 3)

A polypeptide as claimed in claim 3, which expressed in the host cell as a fusion protein.

### Claim 6 (depends on 3)

A polypeptide as claimed in claim 3, which expressed as a fusion protein with the enzyme glutathione s-transferase.

### Claim 7 (depends on 3)

A composition suitable for reducing the severity of T. ovis infection in a ruminant, said composition comprising an effective amount of an antigenic polypeptide as claimed in claim 3 in association with a pharmaceutically acceptable carrier or adjuvant.

### Claim 8

An antigenic T. ovis polypeptide, 45W, essentially free from T. ovis components occurring in nature and running as a 47-52 kDa doublet on SDS-PAGE and reducing the severity of T. ovis infection in a ruminant, said antigenic polypeptide consisting essentially of the amino acid sequence: ##STR3## said antigenic polypeptide 45W being produced by a process comprising (i) culturing a host cell containing an expression vector which encodes and expresses said polypeptide 45W, and
(ii) recovering said antigenic polypeptide 45W free of other naturally occurring T. ovis polypeptides.

### Claim 9 (depends on 1)

A polypeptide as claimed in claim 1, consisting of the amino acid sequence: ##STR4##

### Claim 10 (depends on 1)

A polypeptide claimed in claim 1, consisting of the amino acid sequence: ##STR5##

### Claim 11 (depends on 1)

A peptide fragment of a polypeptide as claimed in claim 1, which generates a protective response to T. ovis infection having a molecular weight of about 26 kDa calculated by SDS-PAGE.

### Claim 12 (depends on 9)

A peptide fragment of a polypeptide as claimed in claim 9, which generates a protective response to T. ovis infection having a molecular weight of 26 kDa calculated by ADS-PAGE.

### Claim 13 (depends on 1)

A polypeptide ,as claimed in claim 1, which is the product of expression of a nucleotide sequence coding therefor in a host cell.

### Claim 14 (depends on 13)

A polypeptide as claimed in claim 13, which is expressed in a host cell as a fusion protein.

### Claim 15 (depends on 14)

A polypeptide as claimed in claim 14, which is expressed as a fusion protein with the enzyme glutathione s-transferase.